Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Duration of Effect of NT 201 in Glabellar Frown Lines
NCT03806933Phase 2Completed
- Sponsor
- Merz
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of incobotulinumtoxinA in glabellar rhytides, sponsored by Merz. Started Jan 2019; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT03806933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806933.